News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Akums Drugs will undertake this development and commercialization in India
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Subscribe To Our Newsletter & Stay Updated
